AstraZeneca

At Agenus, we're driven by a singular, unwavering mission: to end the suffering of cancer patients. For over 30 years, our team of scientists, researchers, and professionals has been united by this purpose, working collaboratively across the US and Europe to discover, develop, and manufacture breakthrough immuno-oncology therapies. Our research and innovation engine has built a comprehensive pipeline of novel immunotherapies that empower the body to recognize and eliminate disease. We believe that the key to transforming cancer treatment lies in harnessing the full power of the immune system - activating it to do what it was meant to do. Our culture is defined by scientific excellence, relentless innovation, and an unwavering focus on patients. We thrive on tackling the toughest challenges in oncology, particularly in areas where current therapies fall short - cold tumors and late-stage cancers that have resisted traditional treatments. The people who thrive here are those who share our passion for making a meaningful difference, who embrace collaboration across disciplines, and who are motivated by the potential to deliver curative therapies to patients who need them most. Every day, we're pushing the boundaries of what's possible in immunotherapy, united by our vision of a future where more patients live longer, fuller lives.

Monte Rosa Therapeutics is a clinical-stage biotechnology company focused on developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. The company’s work centers on degrading proteins - 'Degrading Proteins, Making Medicines' - and advancing precision approaches that target undruggable or inadequately drugged proteins with unprecedented specificity. On its website, the team is described as combining expertise in molecular glue degrader (MGD) chemistry, artificial intelligence (AI), structural biology, and proteomics. Monte Rosa’s QuEEN
9 (Quantitative and Engineered Elimination of Neosubstrates) discovery engine is described as using AI-guided chemistry alongside diverse chemical libraries, structural biology, and proteomics to identify degradable protein targets and rationally design MGDs. The company positions this platform as enabling access to a wide-ranging, differentiated target space across multiple therapeutic areas, and references advancing multiple MGD programs through its pipeline. The company is headquartered in Boston, Massachusetts, and also lists a Basel, Switzerland location on its site.

We're a medicine company that's been turning science into healing for nearly 150 years. Founded in 1876 by Colonel Eli Lilly in Indianapolis, Indiana, we started with a simple mission: create high-quality medicines that meet real needs. Today, our team of about 48,000 people around the world continues that work, combining scientific rigor with genuine care for the patients we serve. We're not just in the business of making medicines - we're committed to growing our business in ways that actually benefit people and society. Every day, we focus on discovering and developing treatments that can make a meaningful difference in people's lives. From diabetes care to obesity treatments and beyond, we work across many therapeutic areas because we know health challenges are complex. But we also know that beyond the science, real impact comes from listening to patients, understanding their needs, and staying true to our founding commitment to quality and integrity. That's what drives us forward.

At ImmunityBio, we're driven by a patient-first culture that guides everything we do. Our team of scientists, doctors, and staff work tirelessly to transform living biological technologies into innovative treatments for cancer and infectious diseases. We believe in empowering the body's own immune system - rather than weakening it - by developing therapies that activate both innate and adaptive immune responses to create durable, complete responses. Our scientific approach centers on a proprietary natural killer cell platform that can be expanded, genetically modified, and cryopreserved. With 27 clinical trials across 13 indications, our lead product ANKTIVA® (N-803) has earned FDA Breakthrough Therapy designation for BCG-unresponsive non-muscle invasive bladder cancer. Founded by Dr. Patrick Soon-Shiong in 2014, we've grown into a clinical-stage biotechnology company with deep expertise in genomics, proteomics, monoclonal antibodies, fusion proteins, vaccines, and autologous and allogeneic cell therapies. Our success is measured not by milestones, but by the quality of life we can offer patients who need these therapies most.

Medtronic exists to solve the world's most challenging health problems through bold innovation and advanced technology. For over 75 years, the company has pioneered groundbreaking health tech that transforms lives, treating more than 70 conditions across the human body - from heart failure to Parkinson's disease. As a global leader in healthcare technology, Medtronic leverages data, AI, and cutting-edge therapies to address complex healthcare challenges that affect millions of people worldwide. With 95,000 employees across 150 countries, the company's mission-driven approach combines medical expertise with technological innovation to restore health, extend life, and alleviate pain for patients everywhere. From its humble beginnings in a Minneapolis garage to becoming the world's largest medical technology company, Medtronic continues to push boundaries and redefine what's possible in healthcare, making a meaningful impact on global health outcomes every day through innovations that put more life into patients' years.

The purpose of Idorsia is to discover, develop, and commercialize innovative medicines to help more patients. We have more ideas, we see more opportunities, and we want to transform the horizon of therapeutic options. Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is a high-potential biopharmaceutical company, specialized in the discovery, development and commercialization of innovative small molecules. Our team is dedicated to bringing innovative medicines from bench to bedside, with operations spanning multiple locations across North America, Europe, and Asia. We conduct research, clinical development, and commercial operations out of these global locations. Idorsia's corporate responsibility efforts encompass employee development and diversity, governance and ethics, as well as the organization's economic, environmental, and social performance.